PROPOSAL: SECOND GENERATION PORTABLE NUCLEAR POWERPLANT. VOLUME IV. PROTOTYPE DEVELOPMENT PROGRAM.

This chapter, utilizing the tools and concepts developed in chapter 5, presents the cases for stage 3 second-generation product and component innovation and for stage 2 design, prototype development, and production engineering. Analyzing these stages, we learn not only how to excel in them, but also their considerable advantages for long-term and equitable local growth compared to trying to copy the Silicon Valley model. A thorough and historical analysis of the growth of the Taiwanese ICT industry is used to make stage 3 lessons concrete. Similarly, for stage 2 we utilize the case of the transformation of the Riviera del Brenta in Northeastern Italy into the most important center in the world for luxury women shoes.

Download Full-text

LIGHTWEIGHT, LOW-BALLISTIC COEFFICIENT, RADIOISOTOPE FUELED CAPSULE PROTOTYPE DEVELOPMENT PROGRAM. Final Report.

10.2172/4035498 ◽

1971 ◽

Author(s):

F.D. Postula ◽

N.B. Elsner ◽

M.R. Emken

Keyword(s):

Development Program ◽

Final Report ◽

Prototype Development ◽

Ballistic Coefficient

Download Full-text

Mechanization in the Maritime Administration Cargo-Ship Replacement Program

Marine Technology and SNAME News ◽

10.5957/mt1.1965.2.2.96 ◽

1965 ◽

Vol 2 (02) ◽

pp. 96-115

Author(s):

Caesar Tangerini ◽

E. Scott Dillon ◽

Carl M. Fixman

Keyword(s):

Research And Development ◽

First Generation ◽

Second Generation ◽

Operating Cost ◽

Development Program ◽

Cost Savings ◽

Fiscal Year ◽

Under Construction

The first generation of mechanization features built into five groups of cargo ships now under construction in the Maritime Administration's replacement program are compared. Commentary is given on the differences in the independent approaches taken together with a brief discussion of additional features appearing in designs for Fiscal Year 1965 ships. Included also is an indication of the Administration's research and development program looking to a future second generation of mechanization for even greater operating-cost savings.

Download Full-text

How bilastine is used to treat allergic rhinitis and urticaria in children

Immunotherapy ◽

10.2217/imt-2021-0251 ◽

2021 ◽

Author(s):

Pablo Rodríguez del Río ◽

Fernando Rodríguez Fernández ◽

Esther Ballester Asensio ◽

Miguel Tortajada-Girbés

Keyword(s):

Allergic Rhinitis ◽

Second Generation ◽

Development Program ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Management Guidelines ◽

Pediatric Dose ◽

Parallel Group ◽

Pediatric Use

Management guidelines for allergic rhinitis and urticaria recommend oral second-generation antihistamines as first-line treatment. The efficacy and safety of bilastine, the newest nonsedating second-generation antihistamine, are well established in adolescents/adults with these allergic conditions. The bilastine development program for pediatric use (2–<12 years) followed EMA-authorized processes. Pharmacokinetic/pharmacodynamic simulation and modeling and a pharmacokinetic study were conducted to identify and confirm the pediatric dose (10 mg/day). A Phase III, multicenter, double-blind, randomized, placebo-controlled, parallel-group study was performed to confirm the safety of bilastine 10 mg/day in children. In this article, evidence is reviewed for use of bilastine in children with allergic rhinoconjunctivitis or urticaria. Several cases are presented which demonstrate its role in routine clinical practice.

Download Full-text